Session » Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis
-
Abstract Number: 268
Inflammatory Bowel Disease In Juvenile Idiopathic Arthritis Patients Upon Biologics
-
Abstract Number: 269
Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment – Results Of The Phase III Program
-
Abstract Number: 270
Canakinumab In The Treatment Of Systemic Juvenile Idiopathic Arthritis: Results From a 12-Week Pooled Post-Hoc Analysis For Efficacy
-
Abstract Number: 271
Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE 3 Study
-
Abstract Number: 272
Predictive Markers Of Joint Damages Of Children With Systemic-Onset Juvenile Idiopathic Arthritis In Long-Term Course Of Treatment With Tocilizumab
-
Abstract Number: 273
Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
-
Abstract Number: 274
Reported Macrophage Activation Syndrome In Patients With Systemic-Onset Juvenile Idiopathic Arthritis Treated With Tocilizumab
-
Abstract Number: 275
Changes In Serum IL-18 Level In Systemic Juvenile Idiopathic Arthritis Patients Who Attained Drug-Free Remission By Tocilizumab
-
Abstract Number: 276
Assessment Of Radiographic Progression In Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From The Tender Trial
-
Abstract Number: 277
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Standardized Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis
-
Abstract Number: 278
Results Of a 24 Month Extension Study In Patients Who Participated In The Trial Of Early Aggressive Therapy In Polyarticular Juvenile Idiopathic Arthritis
-
Abstract Number: 279
Safety and Effectiveness Of Adalimumab In Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 To <4 Years Or ≥4 Years Weighing <15 Kg
-
Abstract Number: 280
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
-
Abstract Number: 281
GO-Kids Imaging Substudy: MRI Treatment Response To 30 Mg/m2 4-Weekly Subcutaneous injections Of Golimumab In Children With Polyarticular JIA – Preliminary Results Of The Open Label Portion
-
Abstract Number: 282
Rates Of Flare-Free Survival In Juvenile Idiopathic Arthritis When Tapering Individual Components Of Tumor Necrosis Factor Inhibitor and Methotrexate Combination Therapy
-
Abstract Number: 283
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
-
Abstract Number: 284
What Is the Relative Priority of the ACR Pediatric Core Set Measures for Youth With Juvenile Idiopathic Arthritis and Their Parents?
-
Abstract Number: 285
Juvenile Idiopathic Arthritis Patients Demonstrate Alterations In HDL Functionality Without Accelerated Subclinical Atherosclerosis
-
Abstract Number: 286
Cardiovascular Risk In Adults With Juvenile Idiopathic Arthritis
-
Abstract Number: 287
Long-Term Evaluation Of Cardiac Function In Juvenile Idiopathic Arthritis Under Anti-Tumor Necrosis Factor Therapy
-
Abstract Number: 288
MRI Findings In Juvenile Spondyloarthopathy and Effects Of Treatment On Subsequent MRI
-
Abstract Number: 289
Development and Validation Of The Cutoff Values For Disease Activity States Of The Three-Item Version Of The Juvenile Arthritis Disease Activity Score
-
Abstract Number: 293
The Efficacy Of Etanercept In Patients With Juvenile Idiopathic Arthritis With Inadequate Response To Infliximab As a First TNF Inhibitor
-
Abstract Number: 294
Physical Activity In Children With Juvenile Idiopathic Arthritis (JIA): The LEAP (Linking Exercise, Activity and Pathophysiology in Childhood Arthritis) Study
-
Abstract Number: 295
Uveitis In The Nordic Juvenile Idiopathic Arthritis Cohort; High Incidence, Frequent Complications, and Gender Associated Risk Factors
-
Abstract Number: 296
Declines In Levels Of Disease Activity and Physical Disability In Children With Juvenile Idiopathic Arthritis Seen In Standard Clinical Care Over The Last 25 Years
-
Abstract Number: 297
Plasma Nicotinamide Phosphoribosyltransferase Correlates With Markers Of Inflammation and May Predict Early Therapeutic Response To Low-Dose Methotrexate In Juvenile Idiopathic Arthritis